Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.

@article{Sambrook2010BisphosphonatesAG,
  title={Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.},
  author={Philip N. Sambrook and Christian Roux and J -P Devogelaer and Kenneth G. Saag and Chak-sing Lau and J -Y Reginster and Christina M. Bucci-Rechtweg and Guoqin Su and David M. Reid},
  journal={Bone},
  year={2010},
  volume={50 1},
  pages={
          289-95
        }
}
BACKGROUND We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177). METHODS Patients received either a single ZOL 5 mg infusion or RIS 5 mg oral daily at randomization, along with calcium (1000 mg) and… CONTINUE READING
Highly Cited
This paper has 20 citations. REVIEW CITATIONS
Tweets
This paper has been referenced on Twitter 5 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 10 citations